Suppr超能文献

新型铂(IV)超分子配合物的合成、晶体结构描述、DNA结合、分子对接及抗癌评估

Synthesis, crystal structural description, DNA binding, molecular docking, and anticancer evaluation of the novel platinum(IV) supramolecular complex.

作者信息

Domyati Doaa, Ali Ehab M M, Hussien Mostafa A, Davaasuren Bambar, Jaremko Mariusz, El-Bendary Mohamed M

机构信息

College of Science, Department of Chemistry, University of Jeddah, 21959, Jeddah, Saudi Arabia.

Biochemistry Department, Faculty of Science, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.

出版信息

BMC Chem. 2025 Apr 18;19(1):102. doi: 10.1186/s13065-025-01472-8.

Abstract

A novel platinum(IV) supramolecular complex; PtCl(2,2'-bipy) was synthesized in aqueous acetonitrile solution at ambient temperature with constant stirring. The structure was confirmed by elemental analysis, FT-IR, UV-vis, NMR spectroscopy, and single-crystal X-ray diffraction, revealing a unique distorted octahedral geometry and a three-dimensional network stabilized by hydrogen bonding and π-π stacking. DNA binding studies, including electronic absorption titration and viscometry, indicated a groove binding mechanism with a binding constant (K) of 5.00 × 10⁶ M. Molecular docking with DNA (PDB ID: 1BNA) and cancer-related proteins (PDB codes: 3ig7, 3eqm, 4fm9) supports these interactions, while in vitro anticancer assays demonstrated potent cytotoxicity with IC₅₀ values of 41.37 μM for HepG2, 47.62 μM for HCT116, and 73.90 μM for MDA-MB-231 cells, outperforming cisplatin in selectivity. This study not only advances our understanding of structure-activity relationships in platinum-based complexes but also highlights the potential of this complex as a promising candidate for developing more effective and less toxic anticancer agents.

摘要

一种新型铂(IV)超分子配合物;PtCl(2,2'-联吡啶)在室温下于乙腈水溶液中通过持续搅拌合成。通过元素分析、傅里叶变换红外光谱(FT-IR)、紫外可见光谱、核磁共振光谱和单晶X射线衍射对其结构进行了确认,结果表明其具有独特的扭曲八面体几何结构以及通过氢键和π-π堆积稳定的三维网络。包括电子吸收滴定和粘度测定在内的DNA结合研究表明其结合机制为沟槽结合,结合常数(K)为5.00×10⁶ M。与DNA(PDB ID:1BNA)和癌症相关蛋白(PDB代码:3ig7、3eqm、4fm9)的分子对接支持了这些相互作用,而体外抗癌试验表明该配合物具有强大的细胞毒性,对HepG2细胞的IC₅₀值为41.37 μM,对HCT116细胞为47.62 μM,对MDA-MB-231细胞为73.90 μM,在选择性方面优于顺铂。这项研究不仅增进了我们对铂基配合物构效关系的理解,还突出了该配合物作为开发更有效、毒性更低的抗癌药物的有前景候选物的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9a5/12008945/f7cfc790bb46/13065_2025_1472_Sch1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验